Pharmacology · CNS

Neurobiology of Depression and Antidepressant Mechanisms

Module 1 — Chapter 17: Antidepressant Drugs

The infographic maps three monoamine systems to their distinct symptom clusters — serotonin deficiency to mood, anxiety, and sleep disruption; norepinephrine deficiency to fatigue, poor concentration, and psychomotor slowing; dopamine deficiency to anhedonia — framing why different antidepressant classes target different symptom profiles.
The drug class table shows that the same reuptake-blocking mechanism underlies SSRIs, SNRIs, and TCAs, but TCAs add muscarinic, histamine H1, and alpha-1 receptor blockade that accounts for their adverse effect burden; MAOIs work upstream by preventing monoamine degradation; and esketamine represents a mechanistic departure by targeting NMDA glutamate receptors rather than monoamine transporters.
The two-to-four-week therapeutic lag is not a drug absorption phenomenon — it is a receptor adaptation process: initial transporter blockade triggers compensatory somatodendritic autoreceptor suppression of neuronal firing, and clinical benefit requires autoreceptor desensitization over weeks; understanding this prevents premature dose escalation or switching.
An adequate antidepressant trial requires four to six weeks at therapeutic dose — one of the most clinically important rules the infographic highlights explicitly, given that inadequate trial duration is a leading cause of apparent treatment resistance.
The indications panels preview content developed in later modules: SSRIs and SNRIs are first-line across multiple anxiety and trauma disorders beyond depression; TCAs have analgesic indications (neuropathic pain, migraine prophylaxis) that outlast their role as antidepressants; bupropion's dopaminergic profile makes it the antidepressant approved for smoking cessation.

Abbreviations: SSRI = selective serotonin reuptake inhibitor · SNRI = serotonin-norepinephrine reuptake inhibitor · TCA = tricyclic antidepressant · MAOI = monoamine oxidase inhibitor · NMDA = N-methyl-D-aspartate · BDNF = brain-derived neurotrophic factor · GAD = generalized anxiety disorder · PTSD = post-traumatic stress disorder · OCD = obsessive-compulsive disorder · PMDD = premenstrual dysphoric disorder

The Monoamine Hypothesis

Monoamine 1

Serotonin

Dorsal raphe → limbic system and prefrontal cortex
Regulates mood, anxiety, sleep, appetite
Deficiency: low mood, anhedonia, anxiety
Target of selective serotonin reuptake inhibitors

Monoamine 2

Norepinephrine

Locus coeruleus → cortex and limbic system
Regulates arousal, attention, stress response
Deficiency: fatigue, poor concentration, psychomotor slowing
Target of serotonin-norepinephrine reuptake inhibitors and tricyclic antidepressants

Monoamine 3

Dopamine

Mesolimbic and mesocortical pathways
Regulates motivation and reward
Deficiency: anhedonia
Target of bupropion

Antidepressant Drug Classes and Targets

Drug Class	Primary Mechanism	Key Agents
Selective serotonin reuptake inhibitors	Block serotonin reuptake transporter	Fluoxetine, sertraline, paroxetine, escitalopram, citalopram, fluvoxamine
Serotonin-norepinephrine reuptake inhibitors	Block serotonin and norepinephrine reuptake transporters	Venlafaxine, duloxetine, desvenlafaxine, levomilnacipran
Tricyclic antidepressants	Block serotonin and norepinephrine transporters plus muscarinic, histamine, alpha-1 receptors	Amitriptyline, nortriptyline, imipramine, desipramine, clomipramine
Monoamine oxidase inhibitors	Block monoamine oxidase A and B enzymes	Phenelzine, tranylcypromine, isocarboxazid, selegiline patch
Atypical antidepressants	Dopamine and norepinephrine reuptake blockade (bupropion); alpha-2 antagonism (mirtazapine)	Bupropion, mirtazapine, trazodone, vilazodone, vortioxetine
Glutamate receptor antagonists	Block N-methyl-D-aspartate receptor	Esketamine (intranasal)

The Two-to-Four-Week Therapeutic Lag

Day 1

Reuptake transporter blocked; synaptic serotonin rises

→

Early weeks

Autoreceptors detect serotonin rise; reduce neuronal firing (negative feedback)

→

Weeks 2–4

Autoreceptors desensitize and downregulate; feedback brake removed

→

Clinical onset

Full serotonergic output restored; mood improvement begins

Clinical Rule

An adequate antidepressant trial = four to six weeks at therapeutic dose. The lag is caused by receptor adaptation, not slow drug absorption. Dose escalation in the first two weeks does not shorten the lag. Do not switch before four to six weeks unless intolerable adverse effects require it.

High-Yield Indications Beyond Depression

Indication group 1

Anxiety and Trauma Disorders

Generalized anxiety disorder: selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors first-line
Panic disorder: selective serotonin reuptake inhibitors first-line
Post-traumatic stress disorder: sertraline and paroxetine approved
Social anxiety disorder: selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors first-line
Obsessive-compulsive disorder: selective serotonin reuptake inhibitors at higher doses; clomipramine for refractory cases

Indication group 2

Pain and Other Conditions

Diabetic peripheral neuropathy: duloxetine approved
Fibromyalgia: duloxetine approved
Neuropathic pain and migraine prophylaxis: amitriptyline and nortriptyline
Smoking cessation: bupropion (Zyban)
Enuresis: imipramine
Premenstrual dysphoric disorder: selective serotonin reuptake inhibitors

Suggested References

Author / Organization	Title	Source
Katzung BG, ed.	Basic and Clinical Pharmacology. 15th ed.	McGraw-Hill; 2021
Brunton LL, Knollmann BC, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed.	McGraw-Hill; 2023
Schildkraut JJ.	The catecholamine hypothesis of affective disorders: a review of supporting evidence.	Am J Psychiatry. 1965;122(5):509–522
Delgado PL, Charney DS, Price LH, et al.	Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan.	Arch Gen Psychiatry. 1990;47(5):411–418
Blier P, de Montigny C.	Current advances and trends in the treatment of depression.	Trends Pharmacol Sci. 1994;15(7):220–226
Castrén E, Rantamäki T.	The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity.	Dev Neurobiol. 2010;70(5):289–297
Casarotto PC, Girych M, Fred SM, et al.	Antidepressant drugs act by directly binding to TRKB neurotrophin receptors.	Cell. 2021;184(5):1299–1313
American Psychiatric Association.	Practice Guideline for the Treatment of Patients with Major Depressive Disorder, 3rd ed.	American Psychiatric Publishing; 2010
Stahl SM.	Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 5th ed. Chapters 7–9.	Cambridge University Press; 2021
Rush AJ, Trivedi MH, Wisniewski SR, et al.	Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.	Am J Psychiatry. 2006;163(11):1905–1917
Ingelman-Sundberg M.	Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity.	Pharmacogenomics J. 2005;5(1):6–13